التفاصيل البيبلوغرافية
| العنوان: |
Dasatinib-induced colitis: clinical, endoscopic and histological findings. |
| المؤلفون: |
Yamauchi, Kenji, Inaba, Tomoki, Colvin, Hugh Shunsuke, Sakakihara, Ichiro, Yamamoto, Kumiko, Izumikawa, Koichi, Takahashi, Sakuma, Tanaka, Shigetomi, Ishikawa, Shigenao, Wato, Masaki, Ando, Midori, Waki, Masato |
| المصدر: |
Scandinavian Journal of Gastroenterology; Apr2022, Vol. 57 Issue 4, p449-456, 8p |
| مصطلحات موضوعية: |
COLITIS, PROTEIN-tyrosine kinase inhibitors, DASATINIB |
| مستخلص: |
Dasatinib, a second-generation tyrosine kinase inhibitor, is widely used in patients with haematological malignancies. The main side effects of dasatinib are myelosuppression and pleural effusion; however, colitis, such as haemorrhagic colitis and cytomegalovirus (CMV) colitis, have been reported as rare side effects. There are only a few studies conducted on dasatinib-induced colitis. This study aimed to clarify the clinical, endoscopic and pathological features of dasatinib-induced colitis. This retrospective study included 51 consecutive patients who received dasatinib therapy between June 2009 and July 2020. Dasatinib-induced colitis was defined as the presence of colitis symptoms, exclusion of other diseases that could cause colitis, and improvement in symptoms after dasatinib withdrawal or dose reduction. CMV positivity was determined based on the positive result of CMV immunostaining. Dasatinib-induced colitis was diagnosed in nine of 51 patients (17.6%), and most of the symptoms were mild diarrhoea and bloody stools. The endoscopic findings were characterised by loss of vascular pattern (100%) and multiple small erosions (83.3%) which were mainly found in the transverse and descending colon. In a patient who underwent follow-up colonoscopy once a year while taking dasatinib, endoscopic findings changed from initial erythematous spots to multiple erosions, and finally to multiple small round elevations with erosion on the top that disappeared after discontinuation of dasatinib. Anti-CMV therapy was administered to one patient, but the treatment failed. All patients with dasatinib-induced colitis were cured after the discontinuation of dasatinib. Physicians should consider CMV reactivation to manage dasatinib-induced colitis. [ABSTRACT FROM AUTHOR] |
|
Copyright of Scandinavian Journal of Gastroenterology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
PDF full text from Publisher